Tiffany Barnes

1.2k total citations
20 papers, 667 citations indexed

About

Tiffany Barnes is a scholar working on Infectious Diseases, Molecular Biology and Virology. According to data from OpenAlex, Tiffany Barnes has authored 20 papers receiving a total of 667 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 10 papers in Molecular Biology and 9 papers in Virology. Recurrent topics in Tiffany Barnes's work include HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (8 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Tiffany Barnes is often cited by papers focused on HIV Research and Treatment (9 papers), HIV/AIDS drug development and treatment (8 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Tiffany Barnes collaborates with scholars based in United States, United Kingdom and South Korea. Tiffany Barnes's co-authors include Lisa M. Galli, Laura W. Burrus, Tatsuhiko Kadowaki, Karl Willert, Michael D. Miller, Tina L. Cheng, Roel Nusse, Kirsten White, Michael E. Abram and Tomáš Cihlář and has published in prestigious journals such as PLoS ONE, Development and Journal of Medicinal Chemistry.

In The Last Decade

Tiffany Barnes

20 papers receiving 656 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tiffany Barnes United States	12	339	298	296	83	80	20	667
Sylvain Thierry France	12	264 0.8×	250 0.8×	234 0.8×	58 0.7×	83 1.0×	21	501
Annika Sanfridson United States	10	251 0.7×	318 1.1×	153 0.5×	120 1.4×	260 3.3×	17	710
Thomas P. Cujec United States	11	613 1.8×	490 1.6×	187 0.6×	79 1.0×	174 2.2×	16	863
Kayo Kurahashi United States	9	383 1.1×	90 0.3×	50 0.2×	83 1.0×	60 0.8×	10	502
Edwige Col France	13	597 1.8×	202 0.7×	87 0.3×	71 0.9×	104 1.3×	17	794
Jean-Philippe Belzile Canada	11	270 0.8×	306 1.0×	123 0.4×	188 2.3×	241 3.0×	13	703
Jonathan Barroso-González Spain	15	422 1.2×	188 0.6×	120 0.4×	110 1.3×	104 1.3×	19	696
Tracy Wolfe United States	4	230 0.7×	136 0.5×	56 0.2×	32 0.4×	32 0.4×	8	347
Maritza Lienlaf United States	9	542 1.6×	289 1.0×	114 0.4×	131 1.6×	301 3.8×	17	836
L M Miles United States	7	207 0.6×	76 0.3×	77 0.3×	78 0.9×	114 1.4×	7	387

Countries citing papers authored by Tiffany Barnes

Since Specialization

Citations

This map shows the geographic impact of Tiffany Barnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiffany Barnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiffany Barnes more than expected).

Fields of papers citing papers by Tiffany Barnes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tiffany Barnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiffany Barnes. The network helps show where Tiffany Barnes may publish in the future.

Co-authorship network of co-authors of Tiffany Barnes

This figure shows the co-authorship network connecting the top 25 collaborators of Tiffany Barnes. A scholar is included among the top collaborators of Tiffany Barnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tiffany Barnes. Tiffany Barnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Tuffy, Kevin M., Anastasia A. Aksyuk, Tyler Brady, et al.. (2023). Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants. The Journal of Infectious Diseases. 228(8). 1055–1059. 2 indexed citations

2.

Kijak, Gustavo H., Vancheswaran Gopalakrishnan, Jagadish Beloor, et al.. (2023). Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial). Infectious Diseases and Therapy. 12(12). 2691–2707. 1 indexed citations

3.

Brady, Tyler, Corinne Cayatte, Tiffany Barnes, et al.. (2023). Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Frontiers in Immunology. 14. 1283120–1283120. 20 indexed citations

4.

Barnes, Tiffany, Tyler Brady, Amy Nguyen, et al.. (2023). Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants. Microbiology Spectrum. 11(2). e0033323–e0033323. 9 indexed citations

5.

Brady, Tyler, Tianhui Zhang, Kevin M. Tuffy, et al.. (2022). Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring. Microbiology Spectrum. 10(5). e0103422–e0103422. 3 indexed citations

6.

Lim, So‐Yon, Christa E. Osuna, Peter Hraber, et al.. (2018). TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Science Translational Medicine. 10(439). 116 indexed citations

7.

Abram, Michael E., Renee R. Ram, Nicolas Margot, et al.. (2017). Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PLoS ONE. 12(2). e0172206–e0172206. 18 indexed citations

8.

Galli, Lisa M., Tiffany Barnes, & Laura W. Burrus. (2016). The Use of Chick Embryos to Study Wnt Activity Gradients. Methods in molecular biology. 1481. 69–80. 1 indexed citations

9.

Navarro, Gabriel, George Stepan, Angela Tsai, et al.. (2015). Abyssomicin 2 Reactivates Latent HIV-1 by a PKC- and HDAC-Independent Mechanism. Organic Letters. 17(2). 262–265. 30 indexed citations

10.

Kulkarni, Rima, Michael E. Abram, Damian J. McColl, et al.. (2014). Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients. HIV Clinical Trials. 15(5). 218–230. 21 indexed citations

11.

Stepan, George, Angela Tsai, G.S. Jones, et al.. (2014). Study of Marine Natural Products Including Resorcyclic Acid Lactones from Humicola fuscoatra That Reactivate Latent HIV-1 Expression in an in Vitro Model of Central Memory CD4+ T Cells. Journal of Natural Products. 77(3). 618–624. 25 indexed citations

12.

Kulkarni, Rima, Michael E. Abram, Damian J. McColl, et al.. (2014). Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients. HIV Clinical Trials. 15(5). 218–230. 19 indexed citations

13.

Abram, Michael E., Derrick Goodman, Kristen Andreatta, et al.. (2013). Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness. Antimicrobial Agents and Chemotherapy. 57(6). 2654–2663. 94 indexed citations

14.

Geleziunas, Romas, George Stepan, George Wei, et al.. (2012). Search for small molecule activators of latent HIV. Retrovirology. 9(S1). 3 indexed citations

15.

Kirschberg, Thorsten, M. Balakrishnan, Neil Squires, et al.. (2009). RNase H Active Site Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Design, Biochemical Activity, and Structural Information. Journal of Medicinal Chemistry. 52(19). 5781–5784. 86 indexed citations

16.

Galli, Lisa M., et al.. (2008). Identification and characterization of subpopulations of Pax3 and Pax7 expressing cells in developing chick somites and limb buds. Developmental Dynamics. 237(7). 1862–1874. 24 indexed citations

17.

Galli, Lisa M., et al.. (2007). Porcupine-mediated lipid-modification regulates the activity and distribution of Wnt proteins in the chick neural tube. Development. 134(18). 3339–3348. 83 indexed citations

18.

Galli, Lisa M., Tiffany Barnes, Tina L. Cheng, et al.. (2006). Differential inhibition of Wnt‐3a by Sfrp‐1, Sfrp‐2, and Sfrp‐3. Developmental Dynamics. 235(3). 681–690. 108 indexed citations

19.

Galli, Lisa M., Tiffany Barnes, Tina L. Cheng, et al.. (2006). Differential inhibition of Wnt‐3a by Sfrp‐1, Sfrp‐2, and Sfrp‐3. Developmental Dynamics. 235(3). 3 indexed citations

20.

Barnes, Tiffany, Lisa M. Galli, Philippa H. Francis‐West, et al.. (2004). Analysis of the role of Sfrps in modulating Wnt-3a activity.. Developmental Biology. 271(2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact